Exploring a Nuclear-Selective Radioisotope Delivery System for Efficient Targeted Alpha Therapy.

Area of Science:

• Nuclear medicine and oncology
• Radiopharmaceutical development
• Cancer cell targeting

Background:

• Targeted alpha therapy (TAT) is a promising cancer treatment modality.
• Effective TAT requires precise delivery of alpha emitters to tumor cells.
• Challenges exist in achieving selective accumulation and minimizing systemic toxicity.

Purpose of the Study:

• To develop an innovative radiolabeled antibody for targeted alpha therapy.
• To selectively deliver the alpha-particle emitter 211At to cancer cell nuclei.
• To evaluate the therapeutic efficacy of the novel agent compared to conventional methods.

Main Methods:

• Fabrication of a novel antibody construct for targeted delivery of 211At.
• Radiolabeling of the antibody with the alpha-particle emitter 211At.
• In vitro and/or in vivo evaluation of the 211At-labeled antibody's targeting and therapeutic effects.

Main Results:

• The developed 211At-labeled antibody demonstrated selective delivery to cancer cell nuclei.
• The novel agent exhibited a superior therapeutic effect compared to conventional counterparts.
• Successful accumulation of alpha-particle emitter achieved at the target site.

Conclusions:

• The innovative 211At-labeled antibody represents a significant advancement in targeted alpha therapy.
• This approach enables organelle-selective drug delivery for enhanced cancer treatment.
• The study supports the potential of this technology for future clinical applications in oncology.